As France moves closer to legalizing medical cannabis, Newsweed and consulting firm Augur Associates have released a comprehensive report titled “State of the Medical Cannabis Industry in France.” This in‑depth study, the result of several months of research, offers a detailed overview of France’s emerging medical cannabis landscape.
A Landscape in Flux
France has made initial progress with a tightly regulated pilot program overseen by ANSM (France’s National Agency for Medicines and Health Products Safety). This trial, which began in March 2021, involves roughly 2,100 patients out of an expected 3,000 and relies exclusively on imported cannabis products—no domestic production has yet been launched .
The central questions now are:
What will France’s permanent legal framework look like?
How will pharmaceutical companies fit into the system?
What will be the healthcare system’s specific requirements?
How will private-sector players be included?
The report answers these questions using strategic analysis, regulatory monitoring, and insights from European experiences.

Intended Audience
The report is aimed at a broad spectrum of stakeholders, including:
Medical cannabis and pharmaceutical companies
Investors and specialized funds
Healthcare professionals
Institutional decision‑makers and policymakers
Journalists and market analysts
Anyone curious about the subject
Its objective is to offer a pragmatic, operationally focused view of France’s upcoming market, framed within the context of varied European regulatory models.
A Pivotal Moment
Released at the end of June 2025, the report—available in both French and English—covers:
The existing regulatory framework and upcoming changes
Key market players and the role of the French healthcare system
A uniquely pharmaceutical approach within Europe
Business barriers and opportunities
Realistic market data
Strategic expert analysis
If France approves a permanent, well-structured model, the implications could significantly impact patients, healthcare providers, and the entire industry.
Free Access and Availability
